ironwoodpharma.com (IRWD) - מקדם חוב לטווח ארוך להון

This price chart for Ironwood Pharmaceuticals (IRWD) demonstrates the 0.00 metric. Ironwood Pharmaceuticals is expanding its portfolio by absorbing promising startups and acquiring new molecules. The firm maintains an impeccable reputation among medical professionals due to the creation of a global bestseller for intestinal therapy. A stable cash flow is ensured by the ownership of the flagship brand Linzess, which has become the benchmark in treating specific gastrointestinal disorders.

For Ironwood Pharmaceuticals (IRWD), the long-term debt-to-equity ratio serves as an indicator of financial stability during the implementation of its M&A strategy and the commercialization of GI drugs. This metric is calculated as the ratio of liabilities with a maturity exceeding one year to total equity, allowing investors to assess the extent of the business's reliance on borrowed funds and the risk of declining liquidity.